Non-immunogenic Staphylokinase in Reperfusion Therapy of Ischemic Stroke in Routine Clinical Practice
Non-interventional Observational Study to Evaluate the Efficacy and Safety of Non-immune Staphylokinase in Reperfusion Therapy of Ischemic Stroke in Routine Clinical Practice
National Society for Neurosonology and Cerebral Circulation
336 participants
Feb 1, 2023
OBSERVATIONAL
Conditions
Summary
The study will collect data from aged 18 to 85 years with a diagnosis of acute stroke, who received thrombolytic treatment with a new agent, nonimmunogenic staphylokinase. Outcomes will be checked for safety and compared to the results of treatment with the other thrombolytic drug, alteplase.
Eligibility
Inclusion Criteria3
- Age 18-85 ;
- Diagnosis of acute ischemic stroke eligible for thrombolytic therapy;
- Thrombolytic therapy with the drug "non-immunogenic staphylokinase" is planned or has already been performed.
Exclusion Criteria3
- Individual intolerance or known hypersensitivity to a recombinant protein containing the amino acid sequence of staphylokinase;
- The presence of a contraindication to thrombolytic therapy of ischemic stroke;
- Pregnancy or lactation.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05697575